KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Tax Provisions (2018 - 2025)

Moderna (MRNA) has disclosed Tax Provisions for 8 consecutive years, with $27.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Tax Provisions rose 142.19% to $27.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $54.0 million, a 217.39% increase, with the full-year FY2025 number at $54.0 million, up 217.39% from a year prior.
  • Tax Provisions was $27.0 million for Q4 2025 at Moderna, up from $13.0 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $1.7 billion in Q3 2023 to a low of -$384.0 million in Q1 2023.
  • A 5-year average of $161.9 million and a median of $27.0 million in 2025 define the central range for Tax Provisions.
  • Peak YoY movement for Tax Provisions: skyrocketed 27762.6% in 2021, then tumbled 233.21% in 2023.
  • Moderna's Tax Provisions stood at $542.0 million in 2021, then plummeted by 64.94% to $190.0 million in 2022, then tumbled by 177.37% to -$147.0 million in 2023, then surged by 56.46% to -$64.0 million in 2024, then surged by 142.19% to $27.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Tax Provisions are $27.0 million (Q4 2025), $13.0 million (Q3 2025), and $7.0 million (Q2 2025).